Natera stock price target raised to $210 from $200 at BTIG on positive cancer trial data
PositiveFinancial Markets

Natera's stock price target has been raised to $210 from $200 by BTIG, following encouraging data from a recent cancer trial. This increase reflects growing confidence in Natera's potential to make significant advancements in cancer diagnostics, which could lead to better patient outcomes and increased market share for the company. Investors are likely to view this as a positive sign for Natera's future.
— Curated by the World Pulse Now AI Editorial System









